

LGD-4033 (10 mg) — Provider White Paper

Advanced Selective Androgen Receptor Modulation for Lean Mass & Performance Support

Dosage Form: Oral Capsules

Strength: 10 mg per capsule

Count: 30 capsules per bottle

Executive Summary

LGD-4033 is an innovative nonsteroidal oral Selective Androgen Receptor Modulator (SARM) developed for precision interaction with androgen receptors and tissue-selective activity.

This compound has become widely recognized in research discussions for its relevance to lean body mass support, strength-related outcomes, and functional performance optimization.

Why LGD-4033 Is Clinically Interesting

Androgen receptors play a central role in:

- lean mass maintenance
- strength and physical performance
- mobility and functional capacity

Natural aging is associated with gradual changes in muscle mass and strength, including effects on type II (fast-twitch) muscle fibers, which are closely linked to power output and functional movement.

LGD-4033 is positioned as a research-forward option aligned with modern clinic goals in:

- body composition improvement
- strength and recovery programs
- longevity and functional aging support

Mechanism of Action (Clinical Overview)

SARMs are a class of androgen receptor ligands designed to provide selective androgen receptor signaling.

LGD-4033 works by:

- entering the cellular cytoplasm and binding to the androgen receptor
- forming a SARM-AR complex that functions as a transcriptional controller
- selectively recruiting cofactors and coregulatory proteins to support targeted tissue responses

This selective cofactor recruitment model is a key reason SARMs are described as a precision approach for anabolic-focused outcomes.

Human Research Highlights

A placebo-controlled study evaluated LGD-4033 dosing for 21 days in healthy men (n=76), ages 21–50.

Outcomes included:

- lean body mass
- muscle strength and stair-climbing power
- hormones and laboratory markers
- PSA and ECG monitoring

Study conclusion:

LGD-4033 supported lean body mass markers within a short interval.

Product Specifications

Product Name: LGD-4033

Strength: 10 mg per capsule

Count: 30 capsules

Route: Oral

This format supports clinic efficiency through:

- consistent capsule dosing
- convenient patient use
- straightforward inventory management

Summary for Clinics

LGD-4033 represents a modern, research-discussed SARM with strong androgen receptor binding and tissue-selective signaling potential.

Its clinical relevance is driven by research interest in lean mass outcomes and performance-support pathways, making it a compelling option for clinics focused on measurable body composition and functional performance programs.

References

Basaria S, Collins L, Dillon EL, et al. The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. *J Gerontol A Biol Sci Med Sci*. 2013;68(1):87–95. doi:10.1093/gerona/gls078.

Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW. Selective androgen receptor modulators: the future of androgen therapy? *Transl Androl Urol*. 2020;9:S135–S148.

Solomon ZJ, Mirabal JR, Mazur DJ, et al. Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. *Sex Med Rev.* 2019;7(1):84–94. doi:10.1016/j.sxmr.2018.09.006.

Bhasin S, Jasuja R. Selective androgen receptor modulators as function promoting therapies. *Curr Opin Clin Nutr Metab Care.* 2009;12(3):232–240. doi:10.1097/MCO.0b013e32832a3d79.